Gold prices steady ahead of Fed decision; weekly weakness noted
SAN JOSE, CA—Amit Kumar, the Chief Executive Officer of Anixa Biosciences Inc (NASDAQ:ANIX), recently acquired 10,000 shares of the company’s common stock. The transaction, dated June 4, 2025, involved a purchase at $2.85 per share, totaling $28,500. According to InvestingPro data, this purchase comes as the stock trades near its Fair Value, with analyst price targets ranging from $7 to $10. Following this acquisition, Kumar’s direct ownership in Anixa Biosciences increased to 569,925 shares. The company maintains a strong liquidity position with a current ratio of 8.89 and holds more cash than debt on its balance sheet. Investors should note that ANIX is scheduled to report earnings on June 6, 2025. For more detailed financial insights and additional ProTips, check out InvestingPro.
In other recent news, Anixa Biosciences has announced several significant developments. The company completed enrollment for a Phase 1 trial of its breast cancer vaccine, developed with Cleveland Clinic and funded by the U.S. Department of Defense. Preliminary data indicates that over 70% of patients showed an immune response, supporting H.C. Wainwright’s reiterated Buy rating and $7 price target. Anixa also secured a Notice of Allowance from the U.S. Patent and Trademark Office for its breast cancer vaccine technology, enhancing its intellectual property portfolio. Furthermore, Anixa received a Notice of Allowance for a patent related to its ovarian cancer vaccine technology, developed in collaboration with Cleveland Clinic and the National Cancer Institute. This patent includes methods for inducing an immune response against the Anti-Mullerian Hormone Receptor, Type II (AMHR2). Dr. Amit Kumar, CEO of Anixa, highlighted the importance of these patents in strengthening the company’s position in cancer vaccine development. H.C. Wainwright maintains a positive outlook on Anixa, underscoring the potential of its vaccine programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.